Latest Governance News

SKS Technologies reported a remarkable doubling of profit in FY25, driven by strong organic growth and a strategic acquisition that positions it for rapid expansion in Australia's largest data centre market.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

Acorn Capital Investment Fund Limited (ACQ) reported a strong FY25 performance with a 15.1% net return and declared 5.5 cents per share in dividends, reinforcing its position in the Australian microcap sector.

ReadCloud Limited reported a 5% revenue increase to $12.9 million for FY25, alongside a 109% surge in underlying EBITDA to $0.76 million, narrowing its statutory loss by 59%. Strong growth in its VET-in-Schools segment and domestic eBooks sales underpinned this improved financial performance.

Abacus Group reported a solid FY25 with modest growth in funds from operations and stable distributions, underpinned by strong leasing activity and a diversified commercial portfolio. The Group also highlighted significant progress in sustainability and reaffirmed its FY26 guidance amid improving market conditions.

Aspermont Limited's trading suspension has been lifted following a key announcement about new board appointments, signaling a fresh chapter for the media publisher.

Aspermont Limited has appointed John Stark and David Straface as interim directors, reinforcing its board with seasoned insiders during a pivotal growth phase focused on data and intelligence services for global resource sectors.

Cazaly Resources has raised $3.5 million through a strongly supported placement to accelerate reverse circulation drilling at its Goongarrie Gold Project in Western Australia. The capital injection positions the company to expand exploration efforts and advance key targets in a promising gold region.

Island Pharmaceuticals has engaged a top Washington DC government affairs firm to accelerate its US biodefence strategy, focusing on its antiviral drug Galidesivir amid promising FDA regulatory signals.

DroneShield Limited has clarified the recent exercise and sale of shares by its directors following performance option vesting, alongside addressing an erroneous contract announcement that was later withdrawn. The company also outlined steps to enhance compliance with ASX continuous disclosure and trading policies.

Stealth Group Holdings has explained the late filing of a director’s interest notice as an administrative oversight, assuring no market harm occurred. The company has since strengthened its compliance controls to prevent future lapses.

Askari Metals Limited’s AS2OC securities have been suspended from trading pending compliance with ASX Listing Rule 2.5, raising questions about the company’s regulatory standing.